Grifols (GIFLF) Other Non-Current Assets (2017 - 2024)
Grifols' (GIFLF) quarterly Other Non-Current Assets came in at $146.4 million in Q4 2024, little changed on a YoY basis from $145.9 million in Q1 2024, and little changed quarter-over-quarter from $145.9 million in Q4 2023.
Analysis
Grifols (GIFLF) Other Non-Current Assets (2017 - 2024) Analysis & Trends
Grifols (GIFLF) has reported Other Non-Current Assets for 8 consecutive years, with $146.4 million the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Other Non-Current Assets changed 0.32% year-over-year to $146.4 million; the trailing twelve-month figure through Dec 2024 stood at $146.4 million (changed 0.32% YoY), and the FY2024 full-year result was $146.4 million, changed 0.32% from the prior year.
- Other Non-Current Assets steadied at $146.4 million in Q4 2024 per GIFLF's latest filing, from $145.9 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.3 billion in Q4 2021 and bottomed at $2.8 million in Q4 2020.
- Historically, Other Non-Current Assets has averaged $431.4 million across 5 years, with a median of $145.9 million in 2023.
- The sharpest annual moves came in 2020 and 2021: Other Non-Current Assets tumbled 97.94% in 2020, then soared 82169.78% in 2021.
- Over 5 years, Other Non-Current Assets stood at $2.8 million in 2020, then jumped by 82169.78% to $2.3 billion in 2021, then plunged by 94.5% to $126.7 million in 2022, then climbed by 15.17% to $145.9 million in 2023, then climbed by 0.32% to $146.4 million in 2024.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $146.4 million, $145.9 million, and $126.7 million for Q4 2024, Q4 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 146.40 Mn |
| Dec 31, 2023 | 145.93 Mn |
| Dec 31, 2022 | 126.71 Mn |
| Dec 31, 2021 | 2.31 Bn |
| Dec 31, 2020 | 2.80 Mn |
| Sep 30, 2020 | 147.64 Mn |
| Mar 31, 2020 | 145.22 Mn |
| Dec 31, 2019 | 136.17 Mn |
| Sep 30, 2019 | 133.28 Mn |
| Mar 31, 2019 | 137.44 Mn |
| Dec 31, 2018 | 128.45 Mn |
| Sep 30, 2018 | 78.26 Mn |
| Mar 31, 2018 | 75.04 Mn |
| Dec 31, 2017 | 77.90 Mn |